Y-mAbs Therapeutics (NASDAQ:YMAB) Issues Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Y-mAbs Therapeutics (NASDAQ:YMAB) released its quarterly earnings results on Tuesday. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02), Zacks reports. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. Y-mAbs Therapeutics updated its Q1 2025 guidance to EPS and its FY 2025 guidance to EPS.

Y-mAbs Therapeutics Stock Down 6.7 %

Y-mAbs Therapeutics stock opened at $5.19 on Tuesday. The firm has a 50-day moving average price of $6.58 and a two-hundred day moving average price of $10.72. The firm has a market capitalization of $232.45 million, a price-to-earnings ratio of -9.61 and a beta of 0.67. Y-mAbs Therapeutics has a 52-week low of $5.13 and a 52-week high of $19.12.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on YMAB shares. HC Wainwright reissued a “buy” rating and issued a $22.00 target price on shares of Y-mAbs Therapeutics in a research report on Monday, January 13th. Brookline Capital Management started coverage on shares of Y-mAbs Therapeutics in a research report on Thursday, December 5th. They issued a “buy” rating and a $17.00 target price for the company. Oppenheimer initiated coverage on shares of Y-mAbs Therapeutics in a research report on Monday, November 18th. They issued an “outperform” rating and a $23.00 target price for the company. Finally, Wedbush reaffirmed an “outperform” rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a report on Monday. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Y-mAbs Therapeutics has a consensus rating of “Buy” and an average price target of $20.89.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.